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Aggregatibacter actinomycetemcomitans Cytolethal Distending Toxin
Activates the NLRP3 Inflammasome in Human Macrophages, Leading
to the Release of Proinflammatory Cytokines
Bruce J. Shenker,a David M. Ojcius,c Lisa P. Walker,a Ali Zekavat,a Monika Damek Scuron,a Kathleen Boesze-Battagliab
Departments of Pathologya and Biochemistry,b University of Pennsylvania School of Dental Medicine, Philadelphia, Pennsylvania, USA; School of Natural Sciences,
University of California, Merced, California, USAc
The cytolethal distending toxin (Cdt) is produced from a number of bacteria capable of causing infection and inflammatory dis-
ease. Our previous studies with Actinobacillus actinomycetemcomitans Cdt demonstrate not only that the active toxin subunit
functions as a phosphatidylinositol-3,4,5-triphosphate (PIP3) phosphatase but also that macrophages exposed to the toxin were
stimulated to produce proinflammatory cytokines. We now demonstrate that the Cdt-induced proinflammatory response in-
volves the activation of the NLRP3 inflammasome. Specific inhibitors and short hairpin RNA (shRNA) were employed to demon-
strate requirements for NLRP3 and ASC as well as caspase-1. Furthermore, Cdt-mediated inflammasome activation is dependent
upon upstream signals, including reactive oxygen species (ROS) generation and Cdt-induced increases in extracellular ATP lev-
els. Increases in extracellular ATP levels contribute to the activation of the P2X7 purinergic receptor, leading to K
 efflux. The
relationship between the abilities of the active toxin subunit CdtB to function as a lipid phosphatase, activate the NLRP3 inflam-
masome, and induce a proinflammatory cytokine response is discussed. These studies provide new insight into the virulence
potential of Cdt in mediating the pathogenesis of disease caused by Cdt-producing organisms such as Aggregatibacter
actinomycetemcomitans.
The cytolethal distending toxins (Cdts) are a family of heat-labile protein cytotoxins produced by several bacterial species,
including Campylobacter jejuni, Shigella species, Haemophilus du-
creyi, Aggregatibacter actinomycetemcomitans, and diarrheal dis-
ease-causing enteropathogens such as some Escherichia coli iso-
lates (1–7). There is clear evidence that Cdts are encoded by three
genes, designated cdtA, cdtB, and cdtC, which are arranged as an
apparent operon (7–12). These three genes specify three polypep-
tides, designated CdtA, CdtB, and CdtC, with apparent molecular
masses of 28, 32, and 20 kDa, respectively, that form a heterotri-
meric holotoxin. Several cell lines and cell types have been shown
to be sensitive to Cdt-induced cell cycle arrest and cell death via
apoptosis; these include human lymphoid cells, fibroblasts, hu-
man embryonic intestinal epithelial cells, a human colon carci-
noma cell line, and human keratinocytes, among others (7, 11,
12). There is considerable agreement that the heterotrimeric ho-
lotoxin functions as an AB2 toxin, where CdtB is the active (A)
unit and the complex of CdtA and CdtC comprises the binding
(B) unit (13–15). In this regard, we have shown that CdtA and
CdtC are required for the toxin to associate with lipid microdo-
mains within lymphocyte membranes and that Cdt-mediated tox-
icity is dependent upon the integrity of these lipid domains (16).
Furthermore, we have demonstrated that the CdtC subunit con-
tains a cholesterol recognition sequence that is required for inter-
actions with membrane cholesterol (16, 17).
The active Cdt subunit CdtB exhibits enzymatic activity, en-
abling it to degrade the signaling lipid phosphatidylinositol-3,4,5-
triphosphate (PIP3), a key component of the phosphatidylinositol
3-kinase (PI-3K) signaling pathway (18, 19). Mutation analysis of
CdtB clearly indicates that the ability of CdtB to induce cell cycle
arrest and cell death in lymphocytes correlates with PIP3 phos-
phatase activity. Furthermore, we have demonstrated that treat-
ment of lymphocytes with Cdt leads to perturbations in PI-3K
signaling, including PIP3 depletion and decreased phosphoryla-
tion of both Akt and glycogen synthase kinase 3 (GSK3), result-
ing in concomitant changes in their respective enzymatic
activities: decreased Akt and increased GSK3 kinase activity.
Moreover, differential susceptibility to the toxin of lymphoid cell
lines with defects in this signaling pathway supports the notion
that CdtB-mediated hydrolysis of PIP3 is key to the molecular
mechanism by which the toxin acts to impair lymphocyte prolif-
eration and survival.
Recently, we reported that human macrophages were not sus-
ceptible to Cdt-induced apoptosis (19). Nonetheless, the toxin
was capable of binding to macrophages and perturbing PI-3K sig-
naling, resulting in decreased phosphorylation of Akt and GSK3;
these changes were also accompanied by concomitant alterations
in kinase activity, as observed with lymphocytes. While Cdt did
not induce apoptosis, treatment of macrophages with toxin re-
sulted in proinflammatory cytokine production, including in-
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creased levels of expression and release of interleukin-1 (IL-1),
tumor necrosis factor alpha (TNF-), and IL-6. Furthermore,
treatment of cells with either Toll-like receptor 2 (TLR-2), TLR-3,
or TLR4 agonists in the presence of Cdt resulted in augmented
proinflammatory responses over those observed with the agonist
alone. These effects were found to be dependent upon the ability
of Cdt to function as a lipid phosphatase and thereby deplete cells
of PIP3, which in turn leads to GSK3 activation. Of particular
importance to these observations, GSK3 activation has been
linked to NF-B activation, which in turn induces increased ex-
pression levels of proinflammatory cytokines, including IL-1,
TNF-, IL-18, and IL-6, among others (20–25). In contrast, the
activation of PI-3K signaling has been linked to the phosphoryla-
tion and inactivation of GSK3, with preferential expression of
anti-inflammatory cytokines such as IL-10 and IL-1 receptor an-
tagonist (IL-1RA) (26–28). We now report that the Cdt-mediated
induction of the proinflammatory cytokine response by macro-
phages is also dependent upon the Cdt-mediated activation of
caspase-1, which in turn is dependent upon the activation of the
NLRP3 inflammasome.
MATERIALS AND METHODS
Cells. The human acute monocytic leukemia cell line THP-1 was obtained
from the ATCC; cells were maintained in RPMI 1640 containing 10% fetal
bovine serum (FBS), 1 mM sodium pyruvate, 20 M 2-mercaptoethanol,
and 2% penicillin-streptomycin at 37°C with 5% CO2 in a humidified
incubator. Preparation of THP-1 cells stably expressing short hairpin
RNA (shRNA) against caspase-1 (shCasp1), NLRP3 (shNLRP3), and ASC
(shASC) as well as nontarget controls was previously described (29–31);
these cells have been well characterized, and expression levels were quan-
tified to be reduced 75% for shNLRP3, 95% for shASC, and 90% for
shCasp1 cells, with no effect on the nontarget controls (32). THP-1 cells
were differentiated into macrophages by incubating cells in the presence
of 50 ng/ml phorbol myristate acetate (PMA) for 48 h, at which time the
cells were washed and incubated an additional 24 h in medium prior to
use.
Expression and purification of Cdt holotoxin. The construction and
expression of the plasmid containing the cdt genes for the holotoxin
(pUCAacdtABChis) were previously reported (33). The plasmids were
constructed so that the cdt genes were under the control of the lac pro-
moter and transformed into E. coli DH5. Cultures of transformed E. coli
cells were grown in 1 liter of LB broth and induced with 0.1 mM isopropyl-
-D-thiogalactopyranoside (IPTG) for 2 h, and bacterial cells were har-
vested, washed, and resuspended in 50 mM Tris (pH 8.0). The cells were
frozen overnight, thawed, and sonicated. The histidine-tagged holotoxin
was isolated by nickel affinity chromatography as previously described
(33); the isolated toxin was analyzed by SDS-PAGE and found to contain
the three Cdt subunits CdtA (18 kDa), CdtB (32 kDa), and CdtC (20 kDa)
(see Fig. S1A in the supplemental material).
Analysis of cytokine release and caspase-1 activation. Cytokine pro-
duction was measured in THP-1-derived macrophages (2  105 cells)
incubated for 5 h (IL-1 and TNF-) or 48 h (IL-18) in the presence or
absence of various amounts of Cdt (0 to 200 ng/ml). Culture supernatants
were collected and analyzed for IL-1 (Quantikine Elisa kit; R and D
Systems), TNF- (Peprotech), and IL-18 (MBL) by enzyme-linked im-
munosorbent assays (ELISAs) using commercially available kits, accord-
ing to the manufacturers’ instructions. In each instance, the amount of
cytokine present in the supernatant was determined by using a standard
curve.
Caspase-1 activity in cells treated with 200 ng/ml Cdt for 2 and 4 h was
determined as described above. Cells were harvested and lysed, and the
extracts were assessed for caspase-1 activity by using a colorimetric assay
(Abcam) based upon the cleavage and release of the chromophore p-
nitroanilide (p-NA) from the labeled substrate Z-Tyr-Val-Ala-Asp(OMe)
(YVAD)–p-NA. Additionally, caspase-1 release into culture supernatants
was assessed by an ELISA using the anti-p20 caspase-1 Quantikine Elisa
kit (R and D Systems).
Western blot analysis. Replicate wells of THP-1-derived macro-
phages (4  106 cells/well) were incubated with Cdt as described above.
The cells were washed and treated with 20 mM Tris-HCl buffer (pH 7.5)
containing 150 mM NaCl, 1 mM EDTA, 1% NP-40, 1% sodium deoxy-
cholate, and protease and phosphatase inhibitors (Pierce); replicate wells
were pooled; and the protein concentration was determined. Samples (30
g) were separated on 12% SDS-PAGE gels and then transferred onto
nitrocellulose. The membrane was blocked with BLOTTO and then incu-
bated with anti-pro-IL-1 or actin antibody (Santa Cruz Biotechnology,
Inc.) for 18 h at 4°C (8). Membranes were washed and incubated with
donkey anti-rabbit immunoglobulin (1:1,000 dilution; GE Healthcare)
conjugated to horseradish peroxidase. The Western blots were developed
by using chemiluminescence and analyzed by digital densitometry
(Kodak Image Systems), as previously described (34).
ATP analysis. Macrophages (4  106) were incubated in medium or
with Cdt (0 to 200 ng/ml) for 4 h. Supernatants were harvested and as-
sayed for ATP content by using a commercially available kit (ATP deter-
mination kit; Molecular Probes). Concentrations of ATP were deter-
mined by using a standard curve.
Statistical analysis. Means  standard errors of the means were cal-
culated for replicate experiments. Significance was determined by using
Student’s t test, differences between multiple treatments were compared
by analysis of variance (ANOVA) paired with Tukey’s honestly significant
difference (HSD) posttest, and a P value of 	0.05 was considered to be
statistically significant.
RESULTS
We previously demonstrated that human macrophages were not
susceptible to the cytotoxic effects of Cdt, which typically involve
cell death resulting from the activation of the apoptotic cascade.
Moreover, we now confirm that Cdt also does not alter cell viabil-
ity, as assessed by propidium iodide exclusion (see Fig. S2 in the
supplemental material). Nonetheless, the toxin is able to bind to
macrophages, deliver CdtB to intracellular compartments, and
perturb PI-3K signaling (19). Moreover, we have shown that a
Cdt-mediated blockade of the PI-3K signaling pathway led to the
expression and release of proinflammatory cytokines; these effects
are consistent with the putative regulatory role for this signaling
pathway in regulating cytokine production. It is well established
that the synthesis of cytokines such as IL-1 requires further pro-
cessing prior to release; this involves enzymatic cleavage leading to
formation of the biologically active mature molecule. In the case
of IL-1 and IL-18, maturation involves caspase-1 activation,
which in turn is dependent upon inflammasome activation. To
determine whether Cdt was able to promote caspase-1 activation,
THP-1-derived macrophages were exposed to 200 ng/ml of toxin
for 2 and 4 h. Cell extracts were assessed for active caspase-1; as
shown in Fig. 1A, toxin-treated cells exhibited 2- to 3-fold in-
creases in caspase-1 activity at 2 and 4 h, respectively. Caspase-1
activation was further demonstrated by Western blotting, which
demonstrated 2.5-fold and 3-fold increases in the amount of
mature caspase-1 (p20) generated in the presence of 250 and 500
ng/ml Cdt, respectively (Fig. 1A, inset). Additionally, the super-
natants of cells treated with Cdt were assessed for the presence of
caspase-1, as the mature/active caspase is typically secreted along
with cytokines. Culture supernatants were analyzed for the secre-
tion of caspase-1 by an ELISA; as shown in Fig. 1B, THP-1-derived
macrophages secreted caspase-1 in a dose-dependent manner.
Macrophages released 4.8  2.3 pg/ml in the presence of 8 ng/ml
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Cdt; caspase-1 secretion increased to 23.3  6.8 pg/ml in the pres-
ence of 200 ng/ml Cdt. Caspase-1 was not detectable in superna-
tants obtained from untreated cells.
Two approaches were initially employed to determine if
caspase-1 activation is required for cytokine maturation and re-
lease following exposure to Cdt. Macrophages were first treated
with various amounts (0.1 to 100 M) of the cell-permeable
caspase-1 inhibitor Z-Trp-Glu(OMe)-His-Asp(OMe)-fluorom-
ethylketone (Z-WEHD-FMK) and then exposed to Cdt (50 ng/
ml), and the supernatants were analyzed 5 h later for IL-1, IL-18,
and TNF- by an ELISA. As shown in Fig. 1C, cells treated with
Cdt alone showed significant IL-1 release (802  107 pg/ml)
relative to that of control cells, which were incubated in medium
alone (9.8  7.8 pg/ml). It should be noted that the induction of
IL-1 production is dependent upon active Cdt, as inactive mu-
tants (19) and heat-inactivated toxin failed to induce the release of
mature IL-1 (see Fig. S2B in the supplemental material); further-
more, polymyxin B did not alter the ability of Cdt to induce
cytokine production (see Fig. S2B in the supplemental material).
Macrophages pretreated with the caspase-1 inhibitor exhibited
dose-dependent reductions in IL-1 release of 608  127, 293 
60, 151  32, and 72  27 pg/ml in the presence of 0.1, 1, 10, and
100 M inhibitor, respectively (Fig. 1C). We have previously
shown that Cdt induces increased cytokine expression and release
of mature IL-1 as a result of a Cdt-mediated PI-3K blockade due
to the ability of CdtB to function as a lipid phosphatase (19).
Therefore, we confirmed that the caspase-1 inhibitor affected only
IL-1 maturation and not the Cdt-induced expression of pro-IL-
1. Figure 1D demonstrates that the caspase-1 inhibitor did not
impair Cdt-induced increases in the synthesis of pro-IL-1; the
proform of the cytokine was upregulated in cells treated with Cdt
alone, and its levels remained elevated in the presence of the toxin
and caspase-1 inhibitor (Fig. 1D). Likewise, cells exposed to Cdt
for 48 h were induced to release 325  8 pg/ml IL-18, whereas
untreated control cells released 38  14 pg/ml (Fig. 1C). Pretreat-
ment with 0.1 M caspase-1 inhibitor reduced IL-18 release to
baseline values (36  23 pg/ml). In contrast to IL-1 and IL-18,
the caspase-1 inhibitor partially blocked TNF- release (Fig. 1D).
Cells exposed to Cdt alone secreted 8,325  276 pg/ml TNF-; in
the presence of 100 M inhibitor, the highest concentration em-
ployed, release was reduced by 56%, to 3,720  109 pg/ml.
The requirement for caspase-1 activation in the Cdt-induced
proinflammatory response was further evaluated with THP-1 cells
that were depleted of the enzyme by using shRNA (Fig. 2). It
should be noted that the characterization of these cells, including
quantification of reduced expression levels relative to those in
nontarget control cells, was previously reported (see Materials and
Methods) (29–32). Cdt induced a dose-dependent release of both
FIG 1 Cdt-induced proinflammatory cytokine release from macrophages is dependent upon caspase-1 activation. (A) THP-1-derived macrophages were treated
with 200 ng/ml Cdt for 2 and 4 h. Cell extracts were assessed for caspase-1 activity as described in Materials and Methods. The inset shows Western blot analysis
of extracts obtained from THP-1-derived macrophages treated with 0 to 500 ng/ml Cdt; the mature form of caspase-1 (p20 subunit) is shown, along with
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as a loading control. Levels of expression are shown below the blot as a percentage of levels in untreated
control cells. OD, optical density. (B) THP-1-derived macrophages were treated with Cdt (0 to 200 ng/ml) for 5 h. Supernatants were then analyzed for the
presence of caspase-1 (anti-p20) by an ELISA. Results are the means  standard errors of the means for three experiments, each performed in triplicate. (C)
Effects of caspase-1 inhibition on release of proinflammatory cytokines. Macrophages were exposed to various amounts of the caspase inhibitor Z-WEHD-FMK
for 60 min; 50 ng/ml Cdt was then added to the cells for 5 h. Culture supernatants were analyzed for IL-1 (circles), IL-18 (diamonds), and TNF- (triangles) by
an ELISA. Results are plotted as the mean  the standard error of the mean pg/ml cytokine released versus the Z-WEHD-FMK concentration. Levels of cytokines
release from untreated control cells were 9.8  7.8 pg/ml (IL-1), 38.1  14.0 pg/ml (IL-18), and 120.9  2.6 pg/ml (TNF-). Asterisks indicate statistical
significance (P  0.05) compared to untreated control cells (A and B) or compared to cells treated with toxin alone (C). (D) Cells were assessed for the expression
of pro-IL-1 after 5 h of exposure to Cdt following solubilization, fractionation by SDS-PAGE, and analysis by Western blotting. Actin is shown as a loading
control. Western blots are representative of results from three experiments.
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IL-1 and IL-18 in macrophages derived from both wild-type and
shRNA control (shCtl) THP-1 cells (Fig. 2A and B). For example,
exposure of shCtl-derived macrophages to 40 and 200 ng/ml Cdt
resulted in 586  82 and 794  138 pg/ml IL-1 as well as 97  10
and 145  8 pg/ml IL-18, respectively. Untreated cells released
100  4 pg/ml IL-1 and 14  9 pg/ml IL-18. In contrast, cytokine
release was significantly reduced in Cdt-treated macrophages de-
rived from cells deficient in caspase-1 (shCasp1); in the presence
of 40 and 200 ng/ml Cdt, these cells secreted 48  26 and 43  15
pg/ml IL-1 as well as 58  14 and 82  11 pg/ml IL-18, respec-
FIG 2 Cdt-induced cytokine release from THP-1-derived macrophages involves activation of the NLRP3 inflammasome. THP-1 cells were stably transfected
with an shRNA that targets caspase-1, NLRP3, or ASC or with nontargeted control shRNA. (A to C) The effect of protein knockdown in cells exposed to 0 to 200
ng/ml Cdt was determined, and culture supernatants were analyzed for IL-1 (A), IL-18 (B), and caspase-1 (p20) (C) release by an ELISA. Results are the means 
standard errors of the means for three experiments performed in triplicate; asterisks indicate a statistically significant difference from the shRNA control P 
0.05). (D) Cells were also analyzed by Western blotting for the presence of pro-IL-1. Actin is shown as a loading control. WT, wild type.
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tively. As expected, these cells were significantly impaired in their
ability to release caspase-1 (Fig. 2C).
Generation of the active form of caspase-1 is dependent upon
the activation of the inflammasome, a multiprotein complex con-
sisting of a nucleotide-binding oligomerization domain-like re-
ceptor (NLR) and an adaptor molecule, such as ASC, along with
procaspase-1 (35, 36). We focused on the NLRP3 inflammasome
and determined the requirement for NLRP3 and ASC by also de-
pleting THP-1 cells of these components with specific shRNAs;
these cells have been well characterized for reductions in expres-
sion levels (see Materials and Methods) (29, 32). Macrophages
derived from NLRP3-deficient cells produced significantly re-
duced levels of cytokines relative to the levels observed in shRNA
control cells (Fig. 2A and B). In the presence of 40 and 200 ng/ml
Cdt, macrophages derived from the NLRP3-depleted cells re-
leased 108  16 and 172  57 pg/ml IL-1 as well as 56  8 and
88  13 pg/ml IL-18, respectively. Similarly, macrophages derived
from ASC-depleted THP-1 cells released reduced levels of IL-1
and IL-18; exposure to 40 and 200 ng/ml Cdt resulted in the re-
lease of 172  61 and 229  92 pg/ml IL-1 along with 54  7 and
77  11 pg/ml IL-18, respectively. In order to confirm that the
reduced expression of inflammasome components also resulted in
a concomitant effect on Cdt-induced caspase activation, we mon-
itored cells for the secretion of caspase-1 (p20). As shown in Fig.
2C, macrophages derived from both wild-type THP-1 and shCtl
cells and exposed to 200 ng/ml Cdt released 77.4  4.7 and 61.0 
2.3 pg/ml caspase-1, respectively, while untreated control cells re-
leased 6  1 pg/ml (wild type) and 4  1 pg/ml (shCtl). Macro-
phages derived from THP-1 cells depleted of NLRP3 or ASC ex-
hibited significant reductions in caspase-1 release in the presence
of 200 ng/ml Cdt, 24  1.6 and 19  1.5 pg/ml, respectively.
Moreover, we confirmed that Cdt-induced expression of pro-
IL-1 was not affected by the disruption of the inflammasome and
reduced caspase-1 activation (Fig. 2D).
Activation of the NLRP3 inflammasome has been linked to a
number of upstream events, which include, among others, reac-
tive oxygen species (ROS) generation, K
 efflux, and increases in
extracellular ATP (37–40). To determine if Cdt-induced activa-
tion of the inflammasome involves ROS, we employed the antiox-
idant N-acetylcysteine (NAC) and the NADPH oxidase inhibitor
diphenylene iodonium (DPI). Pretreatment of THP-1-derived
macrophages with 10 mM NAC followed by Cdt (50 ng/ml) re-
sulted in reductions in the secretion of both IL-1 (174  43
pg/ml) and IL-18 (103  10 pg/ml) compared with cells treated
with toxin alone, which released 384  43 pg/ml IL-1 and 325 
8 pg/ml IL-18 (Fig. 3A). Furthermore, cells pretreated with 250
nM DPI also exhibited reductions in the secretion of both IL-1
(64  35 pg/ml) and IL-18 (131  16pg/ml). In addition to inhib-
iting the release of mature cytokines, these agents also reduced
inflammasome activation, which was reflected by a decline in the
release of caspase-1 (p20); as shown in Fig. 3B, cells pretreated
with NAC and DPI released 17  3 and 13  1 pg/ml caspase-1
(p20), respectively, versus 53  6 pg/ml in cells treated with Cdt
alone. Moreover, these ROS inhibitors had no effect on the Cdt-
induced synthesis of pro-IL-1 (Fig. 3C).
K
 efflux was assessed by using two inhibitory approaches,
increasing the extracellular levels of K
 with 70 mM KCl and with
50 g/ml glibenclamide, a selective inhibitor of ATP-dependent
potassium channels (Fig. 3A). THP-1-derived macrophages were
treated with Cdt (50 ng/ml) in the presence of 70 mM KCl. Levels
of secretion of both IL-1 and IL-18 were reduced to 105  12
pg/ml and 31  18 pg/ml, respectively, compared to 383  43
pg/ml (IL-1) and 325  8 pg/ml (IL-18) in control cells treated
with the toxin alone. Additionally, an inhibitor of ATP-dependent
K
 channels, glibenclamide, reduced cytokine release as well, to
212  16 pg/ml (IL-1) and 22  11 pg/ml (IL-18). In addition to
their effects on cytokine release, these inhibitors also blocked the
release of caspase-1 (p20), to 21  0.4 pg/ml (KCl) and 8  2
pg/ml (glibenclamide) (Fig. 3B); no effect on Cdt-induced pro-
IL-1 levels was observed (Fig. 3C).
ATP has been implicated in the activation of the NLRP3 in-
flammasome via binding to the P2X7 purinergic receptor, which
in turn results in ion permeability, including K
 efflux from the
cytosol (31, 37, 39). The requirement for an ATP-P2X7 interaction
FIG 3 Cdt-induced inflammasome activation involves ROS, K
 efflux, and
extracellular ATP. NAC (10 mM) and DPI (250 nM) were used to determine
the requirement for ROS, elevated extracellular levels of K
 (70 mM) and
glibenclamide (Gli) (50 g/ml) were used to determine the requirement for
K
 efflux, and AZ11645373 (AZ) (1 M) was used to determine the require-
ment for an ATP-PTXR7 interaction. (A and B) Effects of these agents on Cdt
(50 ng/ml)-induced production of IL-1 and IL-18 (A) and on caspase-1 re-
lease (B). Results are the means  standard errors of the means for three
experiments, each performed in triplicate; asterisks indicate statistical signifi-
cance compared to the Cdt-only control (P  0.05). (C) Cells were also ana-
lyzed for the presence of pro-IL-1 by Western blotting. Actin is shown as a
loading control.
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was first assessed by using the P2X7 antagonist AZ11645373. As
shown in Fig. 3A, pretreatment of macrophages with AZ11645373
resulted in reductions in cytokine release of 193  19 pg/ml IL-1
and 93  32 pg/ml IL-18. In addition to cytokine release,
AZ11645373 treatment resulted in reduced caspase-1 release. Cul-
ture supernatants containing both the inhibitor and Cdt (50 ng/
ml) contained 33  4 pg/ml caspase-1 (Fig. 3B), compared to 53 
6 pg/ml in the Cdt control; no effect on Cdt-induced pro-IL-1
levels was observed (Fig. 3C). Similar results were observed for
another P2X7 inhibitor, oxidized ATP (data not shown).
We next determined if Cdt treatment altered extracellular lev-
els of ATP. As shown in Fig. 4A, supernatants obtained from cells
exposed to 100 ng/ml Cdt contained 0.48  0.05 M ATP, while
supernatants from control cells contained 0.25  0.03 M; these
values increased to 0.61  0.09 M in the presence of 200 ng/ml
Cdt. In order to demonstrate that extracellular ATP is required for
inflammasome activation, we utilized the enzyme apyrase. We
first demonstrated that the addition of apyrase to THP-1-derived
macrophage cultures reduces the extracellular ATP burden (Fig.
4B). Cells treated with Cdt (200 ng/ml) exhibited an increase in
the concentration of extracellular ATP to 0.76  0.1 M over that
observed with untreated cells (0.39  0.05 M); in the presence of
apyrase (1 U will liberate 1.0 mol of inorganic phosphate from
ATP or ADP per min at pH 6.5 at 30°C), ATP levels were reduced
in a dose-dependent manner, to 0.34  0.02 M (1 mU), 0.12 
0.02 M (10 mU), and 0.003  0.006 M (100 mU). The super-
natants were also assessed for IL-1 and caspase-1 (p20). As
shown in Fig. 4C, treatment of cells with 200 ng/ml Cdt resulted in
an increase in IL-1 secretion to 474  9.4 pg/ml, in contrast to
50  16.9 pg/ml in untreated cells. The addition of 1 mU apyrase
to Cdt-treated cells resulted in reduced IL-1 release, to 70  9.4
pg/ml; treatment with 100 mU apyrase further reduced the cyto-
kine level to 44.1  5.6 pg/ml. Apyrase had a similar effect on
caspase-1 release, which was not detected at any enzyme concen-
tration used, while supernatants from Cdt-treated cells contained
87  2.2 pg/ml.
We previously demonstrated that the proinflammatory cyto-
kine response induced by Cdt was mediated at the molecular level
by the action of the active Cdt subunit CdtB, functioning as a PIP3
phosphatase. PIP3 depletion led to a blockade of the PI-3K signal-
ing pathway, decreased phosphorylation of GSK3, and a con-
comitant activation of this kinase. In those studies, GSK3 inhib-
itors were effectively used to block the release of proinflammatory
cytokines. Therefore, in a final series of experiments, we employed
three kinase inhibitors to determine if Cdt-induced activation of
GSK3 was responsible for both the expression of pro-IL-1 as
well as increases in extracellular ATP levels. As shown in Fig. 5A,
macrophages preexposed to each of the GSK3 inhibitors, 10 M
GSK inhibitor X, 50 M GSK inhibitor XII, and 1 M GSK inhib-
itor XV, exhibited a reduction in the pro-IL-1 expression level
relative to that in cells treated with the toxin alone. The GSK in-
hibitors were also assessed for their ability to alter Cdt-induced
increases in extracellular ATP levels. Supernatants obtained from
cells exposed to Cdt alone contained 0.57  0.03 M ATP, versus
0.35  0.04 M in control cells. In contrast, cells pretreated with
each of the inhibitors exhibited significant reductions in the
levels of extracellular ATP: 0.34  0.04 M (GSK inhibitor X),
0.33  0.02 M (GSK inhibitor XII), and 0.35  0.02 M (GSK
inhibitor XV).
DISCUSSION
In previous studies, we demonstrated that monocytes as well as
macrophages derived from either human monocytes or the acute
monocytic leukemia cell line THP-1 exhibit increases in cytokine
gene expression and protein secretion following exposure to A.
actinomycetemcomitans Cdt (19). Specifically, Cdt-treated macro-
phages were induced to produce IL-1, TNF-, and IL-6 within 5
h; we now show that IL-18 is also released by macrophages ex-
posed to toxin for 48 h. Furthermore, previous studies demon-
strated that Cdt-induced cytokine release was dependent upon the
FIG 4 The proinflammatory response induced by Cdt is dependent upon
extracellular ATP. (A) Macrophages were treated with 0 to 200 ng/ml Cdt for
2 h, and supernatants were then analyzed for ATP. (B and C) Cells were also
analyzed for the effect of apyrase (Pyrase) on extracellular ATP levels (B) as
well as IL-1 release (open bars) and caspase-1 release (solid bars) (C). Results
represent the means  standard errors of the means for three experiments,
each performed in triplicate; asterisks indicate statistical significance com-
pared to control cells (P  0.05).
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active Cdt subunit CdtB and its ability to function as a PIP3 phos-
phatase. This activity led to a perturbation of PI-3K signaling,
resulting in decreased PIP3 levels and reduced phosphorylation of
Akt and GSK3. Decreased GSK3 phosphorylation resulted in
increases in its kinase activity; moreover, the ability of Cdt to
induce cytokine release was reduced when it was added to cells in
the presence of GSK3 inhibitors. It should also be noted that
CdtB mutants deficient in lipid phosphatase activity yet retaining
DNase activity failed to induce cytokine release, as did mutants
lacking both enzymatic activities (19).
IL-1 and IL-18 are synthesized as inactive precursors that
require proteolytic cleavage for activation and secretion, resulting
in the generation of mature forms with potent proinflammatory
activities. In this study, we explored the events that govern the
maturation of IL-1 and IL-18 following exposure of macro-
phages to Cdt. A key event in this process is the activation of
caspase-1, which is also synthesized as an inactive proenzyme.
Procaspase-1 requires further processing involving dimerization
and autoproteolytic cleavage, which results in the generation of
the subunits p20 and p10. Indeed, we demonstrate that Cdt in-
duces time-dependent caspase-1 activation. Also, macrophage
culture supernatants are typically utilized to detect the mature
caspase-1 subunits, as they are not only found in the cytoplasm
but also secreted along with active cytokines (30, 41). Thus, it was
not surprising that Cdt-treated macrophages released caspase-1 at
elevated levels, which were dependent upon the Cdt concentra-
tion. Furthermore, pretreatment of cells with the caspase-1 inhib-
itor Z-WEHD-FMK blocked the Cdt-induced release of both
IL-1 and IL-18 but did not affect Cdt-induced expression of
pro-IL-1. In addition to using the caspase-1 inhibitor, we also
confirmed that Cdt-induced IL-1 and IL-18 release was
caspase-1 dependent by silencing its expression in THP-1 cells
using RNA interference. Cdt-treated caspase-1 knockdown cells
exhibited significantly reduced levels of caspase-1 release; addi-
tionally, a concomitant reduction in IL-1 and IL-18 release was
also observed in these cells. It should be noted that the caspase-1-
deficient cells were not altered in their ability to synthesize pro-
IL-1 in response to Cdt.
Caspase-1 activation is dependent upon the formation of mul-
tiprotein complexes known as inflammasomes (35, 36). Typically,
the inflammasome is composed of a receptor or sensor, such as the
nucleotide-binding domain leucine-rich repeat (NLR) protein,
and an adaptor molecule, such as apoptosis-associated speck-like
protein containing a CARD (caspase recruitment domain) (ASC),
that tethers the complex to procaspase-1. The group of human
NLR proteins contains several members, 14 of which belong to the
NLR protein family; one member of this family, NLRP3, is a com-
ponent of one of the best-studied inflammasome complexes and
has also been reported to be activated by microbial-derived li-
gands, including toxins (reviewed in references 36 and 42). Fur-
thermore, it has been shown that exposure of human monocytes
to A. actinomycetemcomitans results in the upregulation of
NLRP3, regardless of whether the bacteria were able to express
toxins such as Cdt and the leukotoxin; however, that report did
not indicate whether the inflammasome was activated or if mature
cytokines were secreted (43). Therefore, we chose to initially focus
our studies on the role of the NLRP3 inflammasome and deter-
mine if, in addition to caspase-1, NLRP3 as well as the adaptor
molecule ASC are required for Cdt-induced caspase-1 activation
and cytokine release. Indeed, silencing of the expression of either
NLRP3 or ASC confirmed the requirement for these components
in the Cdt-induced proinflammatory response. We observed a
significant reduction in the release of caspase-1 following treat-
ment of macrophages with Cdt; moreover, the release of both
IL-1 and IL-18 was also reduced. It should be noted that the
ASC- and NLRP3-deficient cells were not impaired in their ability
to upregulate the synthesis of pro-IL-1 in response to Cdt.
Interestingly, the Cdt-induced release of TNF- was partially
reduced (50%) by pretreatment with the caspase-1 inhibitor.
Moreover, cells transfected with shRNA for caspase-1, ASC, or
NLRP3 also exhibited a reduction in TNF- release (80%) in
response to the toxin. The reduced release of TNF- was unex-
pected, as this cytokine typically does not require further process-
ing by caspase-1. These results suggest that a portion of Cdt-in-
duced TNF- release may be the result of toxin-induced IL-1
production and its action on autocrine networks. In this context,
it should be noted that several investigators have demonstrated
cross-regulation between IL-1/IL-18 processing and the process-
ing of other inflammatory cytokines (44). For example, it has been
shown that ASC is responsible for the induced expression of sev-
eral cytokines, including TNF-. It is not clear at this time if any of
FIG 5 GSK3 activation contributes to Cdt-induced expression of pro-IL-1
and increased extracellular ATP levels. (A) THP-1-derived macrophages were
pretreated with GSK inhibitors for 1 h, followed by the addition of 200 ng/ml
Cdt. After 4 h, cells were fractionated by SDS-PAGE and analyzed by Western
blotting for pro-IL-1. Results are representative of three experiments. (B)
Macrophages were pretreated with GSK inhibitors as described above and then
treated with 200 ng/ml Cdt for 4 h. Supernatants were analyzed for ATP as
described in Materials and Methods. Results represent the means  standard
errors of the means for three experiments; asterisks indicate statistical signifi-
cance compared to control cells treated with Cdt alone (P  0.05).
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these cross-regulatory events are involved in the proinflammatory
cytokine response induced by Cdt.
Inflammasome activation and the subsequent release of
caspase-1, IL-1, and IL-18 require additional signals, often re-
ferred to as danger signals, from stressed or infected cells. Of par-
ticular interest is the role of extracellular ATP, which is involved in
intercellular communication that involves both lytic and nonlytic
stimuli; in this capacity, ATP serves as an agonist for P2 nucleotide
receptors such as P2X7 (reviewed in references 45 and 46). The
P2X7 receptor is highly expressed on monocytes, macrophages,
and lymphocytes, and its activation following an association with
ATP contributes to the assembly of the NLRP3 inflammasome
(37, 47). Thus, our observations are consistent with a mechanism
involving Cdt-induced ATP-dependent activation of the puriner-
gic receptor, as not only do toxin-treated cells exhibit increased
levels of extracellular ATP, but the addition of apyrase also reduces
these ATP levels as well as the release of caspase-1 and mature
IL-1. Moreover, pretreatment of cells with the P2X7 receptor
inhibitor AZ11645373 reduced both caspase-1 release and the se-
cretion of IL-1 and IL-18; no effect on the toxin-induced expres-
sion of pro-IL-1 was observed. Similar results were also observed
with oxidized ATP, another P2X7 inhibitor (data not shown).
It is noteworthy that the NLRs were originally proposed to
serve as sensors of activating signals such as microbial ligands;
however, their role has been expanded to include serving as
switches for cellular signals in response to stress resulting from
infection (reviewed in references 35 and 36). Furthermore, it has
been proposed that NLRP3 is capable of sensing imbalances in the
concentrations of ROS and intracellular ions, in particular K
.
Thus, Cdt-mediated increases in extracellular ATP levels and
ATP-induced P2X7 activation likely contribute to NLRP3 assem-
bly and activation through ROS generation and/or reduced intra-
cellular concentrations of K
. To address these possibilities, we
employed high levels of extracellular K
 as well as the K
 channel
blocker glibenclamide to impede ion efflux. Our results clearly
demonstrate that potassium efflux is critical to the Cdt-induced
proinflammatory response, as inhibition by both agents pre-
vented the activation of caspase-1 and the release of IL-1 and
IL-18. These inhibitors did not interfere with Cdt-induced expres-
sion of pro-IL-1. As ROS are typically generated from the mito-
chondrial electron transport chain and/or plasma membrane-as-
sociated NADPH oxidase, two inhibitors were employed to
demonstrate that ROS generation was involved in the Cdt-in-
duced activation of caspase-1 and the release of cytokines: DPI, an
inhibitor of NADPH oxidase, and NAC, an antioxidant. Both
agents reduced the release of caspase-1 as well as IL-1 and IL-18;
the Cdt-induced expression of pro-IL-1 was not affected by these
agents. Since reduced intracellular levels of K
 have been linked to
triggering of ROS generation (31), we also assessed the effect of
Cdt on macrophage ROS generation. While THP-1-derived mac-
rophages constitutively generate low levels of ROS, Cdt treatment
did not alter these levels (data not shown). Thus, it appears that
endogenous levels of ROS along with ATP-dependent reductions
in the intracellular levels of K
 contribute to NLRP3 inflam-
masome activation in the presence of Cdt.
We propose that Cdt induces a proinflammatory cytokine re-
FIG 6 Summary diagram depicting the mechanism by which Cdt induces a proinflammatory cytokine response in macrophages. Two signals are proposed. The
first signal (pink arrows) involves the upregulation of inflammatory cytokine gene and protein expression; this signal is dependent upon Cdt’s abilities to function
as a PIP3 phosphatase, block PI-3K signaling, and activate GSK3, leading to the expression and synthesis of pro-IL-1 and IL-18. The second signal (blue
arrows) involves the activation of the NLRP3 inflammasome, which requires the generation of extracellular ATP, an ATP-P2X7 interaction, K

 efflux, and
utilization of endogenous ROS. Inhibitors of GSK3 also block ATP generation, suggesting that Cdt-induced activation of this kinase is also critical to
ATP-dependent inflammasome activation.
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sponse via a two-step process, as summarized in Fig. 6. First, ex-
posure to the toxin results in upregulation of both cytokine gene
expression and protein synthesis, which results in elevated intra-
cellular levels of both pro-IL-1 and IL-18 as well as TNF- and
IL-6. As previously demonstrated and as corroborated by this
study, this response is dependent upon the active toxin subunit
CdtB functioning as a PIP3 phosphatase. Depletion of PIP3 results
in a blockade of the PI-3K signaling cascade and, in particular, a
decrease in the phosphorylation of GSK3 and a concomitant
increase in its kinase activity (19). Activation of GSK3 is critical
for NF-B activation and expression of proinflammatory cyto-
kines. Although these events are dependent upon GSK3 activa-
tion, they alone are not sufficient to induce the maturation and
release of IL-1 and IL-18. Thus, we further propose that a second
signal is required, which involves the activation of the NLRP3
inflammasome. Our studies support a model in which Cdt-medi-
ated activation of the inflammasome is dependent upon toxin-
induced increases in extracellular ATP levels; moreover, these ob-
servations suggest that the increases in ATP levels are also
dependent upon Cdt-induced GSK3 activation. Furthermore,
we propose that the increase in the extracellular ATP level contrib-
utes to the activation of the purinergic receptor P2X7 and K


efflux. These events, together with the endogenous generation of
ROS, lead to the activation of the NLRP3 inflammasome and the
release of mature IL-1 and IL-18.
It should be noted that in addition to lipid phosphatase activ-
ity, CdtB also exhibits DNase activity. While PIP3 phosphatase
activity is almost comparable to those of other lipid phosphatases,
its DNase activity is considerably less than that associated with
DNase I (18). Nonetheless, DNase activity has been shown to be
critical for toxicity to a number of cell types, such as CHO and
HeLa cells, among others, which typically require high doses of
toxin (1, 7). Lipid phosphatase activity is critical to lymphocyte
toxicity, which requires low doses of toxin (18). Macrophages,
which are not killed by Cdt, exhibit a proinflammatory cytokine
response when exposed to toxin; this response to Cdt is dependent
upon PIP3 phosphatase activity. We have previously demon-
strated that Cdt induces a PI-3K blockade due to PIP3 depletion in
macrophages, and furthermore, the proinflammatory response
was eliminated with CdtB mutants lacking lipid phosphatase ac-
tivity (19). Moreover, the Cdt-induced cytokine response from
macrophages requires GSK3 activation, a result of a PI-3K sig-
naling blockade (19). Consistent with this notion, we demonstrate
that GSK3 inhibitors block the proinflammatory response, in-
cluding synthesis of both cytokines and ATP.
Collectively, our results are consistent with the clinical picture
associated with A. actinomycetemcomitans infection and peri-
odontal disease, which are characterized by the presence of this
organism in large numbers in biofilms associated with tooth sur-
faces, inflammation, and the destruction of periodontal tissue
(48–51). We now propose that a significant contributing factor to
A. actinomycetemcomitans-induced disease is derived from the
proinflammatory actions of Cdt. However, it is not clear if these
actions contribute to host defense and thereby serve to limit dis-
ease progression and/or severity or whether Cdt represents a vir-
ulence factor contributing to inflammation and tissue injury. It is
also likely that a Cdt-mediated proinflammatory response could
also promote and sustain infection by providing degraded tissue
protein fragments and hemin that fuel the nutritional needs of
bacteria (51). In conclusion, it is likely that these observations
have implications not only for the pathogenesis of disease caused
by A. actinomycetemcomitans but also for other infectious and
chronic inflammatory disorders that occur in association with the
wide range of Cdt-producing pathogens.
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